Long-term lamivudine therapy in hepatitis B-associated membranous nephropathy?

Kidney International

Volumn 69, Issue 4, 2006, Pages 776-

  Ng, Y Y ^a   Yang, W C ^a   Lee, S T ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

DISEASE ASSOCIATION; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FUNCTION; LETTER; LONG TERM CARE; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; REMISSION; VIRUS MUTATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GLOMERULONEPHRITIS, MEMBRANOUS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION; REMISSION INDUCTION; TIME FACTORS;

EID: 32544443057     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000171     Document Type: Letter

References (4)

1. Tang S, Lai FMM, Lui YH et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68: 1750-1758.
2. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1717.
3. Lok AS, Lai CL, Leung N et al. Long term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722.
4. Shibolet O, Ilan Y, Gillis S et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396.